Citadel Advisors
SCNI

Citadel Advisors’s Scinai Immunotherapeutics SCNI Stock Holding History

Citadel Advisors’s Portfolio SCNI Stock Details SCNI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.7K Buy
+6,226
New +$30.6K ﹤0.01% 13450
2026
Q1 		– Sell
-3,456
Closed -$24.6K – 14087
2025
Q4 		$24.6K Buy
3,456
+593
+21% +$6.76K ﹤0.01% 12284
2025
Q3 		$36.2K Buy
2,863
+1,703
+147% +$29.6K ﹤0.01% 12331
2025
Q2 		$26.6K Buy
+1,160
New +$29.2K ﹤0.01% 12032
2024
Q2 		– Sell
-122
Closed -$6.31K – 15258
2024
Q1 		$6.31K Buy
+122
New +$6.29K ﹤0.01% 13685
2023
Q1 		– Sell
-175
Closed -$51.9K – 15420
2022
Q4 		$51.9K Buy
+175
New +$132K ﹤0.01% 12089
2022
Q3 		– Sell
-24
Closed -$28K – 13499
2022
Q2 		$28K Sell
24
-18
-43% -$24.7K ﹤0.01% 12266
2022
Q1 		$70K Buy
+42
New +$61K ﹤0.01% 12578
2021
Q4 		– Sell
-18
Closed -$40K – 14650
2021
Q3 		$40K Buy
+18
New +$46.2K ﹤0.01% 13470
2021
Q2 		– Sell
-29
Closed -$111K – 14331
2021
Q1 		$111K Buy
+29
New +$127K ﹤0.01% 12383
2017
Q2 		– Sell
-31
Closed -$177K – 7996
2017
Q1 		$177K Buy
+31
New +$160K ﹤0.01% 6609

Other funds holding SCNI

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
SG
StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return
CAPTRUST Financial Advisors
CAPTRUST Financial Advisors Raleigh, North Carolina $65.5B AUM 24.25% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Citadel Advisors's SCNI Position: Q2 2026 in Review

Citadel Advisors opened a new position in Scinai Immunotherapeutics (SCNI) in Q2 2026: 6,226 shares worth $15.7K. The stake represents ﹤0.01% of the portfolio and ranks #13450 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in SCNI as recently as Q4 2025.

Citadel Advisors first reported a position in SCNI in Q1 2017 and has held it in 11 quarters since. The position peaked at $177K in Q1 2017. 11 funds tracked by Wall St. Rank hold SCNI as of Q2 2026.

  • Citadel Advisors held 6,226 shares of Scinai Immunotherapeutics worth $15.7K as of Q2 2026.
  • Scinai Immunotherapeutics was a new Citadel Advisors position in Q2 2026.
  • Scinai Immunotherapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #13450 holding.
  • Citadel Advisors first reported a position in Scinai Immunotherapeutics in Q1 2017 and has held it in 11 quarters since.
  • Citadel Advisors's Scinai Immunotherapeutics position peaked at $177K in Q1 2017.
  • 11 funds tracked by Wall St. Rank held Scinai Immunotherapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.